Abstract
Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Keywords: Receptor, channel, patch clamp, kinetics
Current Neuropharmacology
Title: Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids
Volume: 8 Issue: 1
Author(s): Gustav Akk, Douglas F. Covey, Alex S. Evers, Steven Mennerick, Charles F. Zorumski and Joe Henry Steinbach
Affiliation:
Keywords: Receptor, channel, patch clamp, kinetics
Abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Export Options
About this article
Cite this article as:
Akk Gustav, Covey F. Douglas, Evers S. Alex, Mennerick Steven, Zorumski F. Charles and Steinbach Henry Joe, Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909458
DOI https://dx.doi.org/10.2174/157015910790909458 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Activation of Human Platelets by 2-Arachidonoylglycerol: Role of PKC in NO/cGMP Pathway Modulation
Current Neurovascular Research Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Structural and Functional Organization of miRNAs
Current Pharmacogenomics Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets Does A Subclinical Cardiotoxic Effect of Clozapine Exist? Results from a Follow-up Pilot Study
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemokine Receptors as Anti-Retroviral Targets
Current Drug Targets Selective Dopamine D4 Receptor Antagonists: Review ofStructure-Activity Relationships
Current Medicinal Chemistry - Central Nervous System Agents Neuroprotection of Dietary Virgin Olive Oil on Brain Lipidomics During Stroke
Current Neurovascular Research Role of Fractalkine (CX3CL1) in Regulating Neuron-Microglia Interactions: Development of Viral-Based CX3CR1 Antagonists
Current Alzheimer Research Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations
Current Pharmaceutical Design Meet the Editorial Board
Current Alzheimer Research Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Rescue of Hypovitaminosis A Induces Non-Amyloidogenic Amyloid Precursor Protein (APP) Processing
Current Alzheimer Research Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients
Current Alzheimer Research Multi-potent Natural Scaffolds Targeting Amyloid Cascade: In Search of Alzheimer's Disease Therapeutics
Current Topics in Medicinal Chemistry Therapeutic Strategies in Parkinsons Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Metal Recycling Technologies for Battery Waste
Recent Patents on Engineering Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics